Depression, PostpartumPhase 3NCT04442503
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
A Phase 3 study testing SAGE-217 in people with Depression, Postpartum, run by Biogen at 82 sites in 3 countries.
Trial summary
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Depression, Postpartum
- What is being tested?
- SAGE-217
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 82 sitesin 3 countries
- Study dates
- 8 Jun 2020to 12 Apr 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP.
- Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT).
- Participant is ≤12 months postpartum at screening and Day 1.
Who cannot join
- Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD.
- Participant has active psychosis per investigator assessment.
- Participant has a medical history of nonfebrile seizures.
- Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
- Participant has a history of sleep apnea.
- Note: Other protocol-defined inclusion/exclusion criteria applied.
Trial locations and contacts
82 sites in 3 countries.
82 sites in 3 countries
United States68 sites
Sage Investigational Site
Allentown, Pennsylvania, 18104
Sage Investigational Site
Alpharetta, Georgia, 30022
Sage Investigational Site
Anaheim, California, 92805
Sage Investigational Site
Atlanta, Georgia, 30331
Sage Investigational Site
Aurora, Colorado, 80045
Sage Investigational Site
Beachwood, Ohio, 44122
Sage Investigational Site
Bellevue, Washington, 98007
Sage Investigational Site
Bellflower, California, 90706
Sage Investigational Site
Bentonville, Arkansas, 72712
Sage Investigational Site
Beverly Hills, California, 90212
Sage Investigational Site
Boston, Massachusetts, 02114
Sage Investigational Site
Boynton Beach, Florida, 33435
Sage Investigational Site
Brooklyn, New York, 11229
Sage Investigational Site
Chapel Hill, North Carolina, 27599
Sage Investigational site
Charleston, South Carolina, 29425
Sage Investigational Site
Charlotte, North Carolina, 28211
Sage Investigational Site
Costa Mesa, California, 92627
Sage Investigational Site
Dallas, Texas, 75231
Sage Investigational Site
Decatur, Georgia, 30030
Sage Investigational Site
Denver, North Carolina, 28037
Sage Investigational Site
Detroit, Michigan, 48201
Sage Investigational Site
Flowood, Mississippi, 39232
Sage Investigational Site
Fort Worth, Texas, 76104
Sage Investigational Site
Glen Oaks, New York, 11004
Sage Investigational Site
Hialeah, Florida, 33012
Sage Investigational Site
Hoffman Estates, Illinois, 60169
Sage Investigational Site
Houston, Texas, 77058
Sage Investigational Site
Idaho Falls, Idaho, 83404
Sage Investigational Site
Imperial, California, 92251
Sage Investigational Site
Jacksonville, Florida, 32256
Sage Investigational Site
Las Vegas, Nevada, 89102
Sage Investigational Site
League City, Texas, 77573
Sage Investigational Site
Lemon Grove, California, 91945
Sage Investigational Site
Lincolnwood, Illinois, 60712
Sage Investigational Site
Marlton, New Jersey, 08053
Sage Investigational Site
Mayfield Heights, Ohio, 44124
Sage Investigational Site
Miami, Florida, 33133
Sage Investigational Site
Miami Springs, Florida, 33166
Sage Investigational Site
Miramar, Florida, 33029
Sage Investigational Site
Moosic, Pennsylvania, 18507
Sage Investigational Site
New Orleans, Louisiana, 70115
Sage Investigational Site
New York, New York, 10036
Sage Investigational SIte
North Canton, Ohio, 44720
Sage Investigational Site
North Chesterfield, Virginia, 23235
Sage Investigational Site
Norwalk, California, 90650
Sage Investigational Site
Norwich, Connecticut, 06360
Sage Investigational Site
Oceanside, California, 92056
Sage Investigational Site
Oklahoma City, Oklahoma, 73112
Sage Investigational Site
Orange, California, 92866
Sage Investigational Site
Orange, California, 92868
Sage Investigational Site
Orlando, Florida, 32801
Sage Investigational Site
Orlando, Florida, 32807
Sage Investigational Site
Pensacola, Florida, 35202
Sage Investigational Site
Pinellas Park, Florida, 33872
Sage Investigational Site
Pompano Beach, Florida, 33060
Sage Investigational Site
Providence, Rhode Island, 02904
Sage Investigational Site
Redlands, California, 92374
Sage Investigational Site
Richardson, Texas, 75080
Sage Investigational Site
Saint Charles, Missouri, 63304
Sage Investigational Site
San Antonio, Texas, 78229
Sage Investigational Site
San Bernardino, California, 92408
Sage Investigational Site
Savannah, Georgia, 31405
Sage Investigational Site
Scottsdale, Arizona, 85258
Sage Investigational Site
Sherman Oaks, California, 91403
Sage Investigational Site
St Louis, Missouri, 63125
Sage Investigational Site
St Louis, Missouri, 63128
Sage Investigational Site
Torrance, California, 90502
Sage Investigational Site
Wichita, Kansas, 67226
Spain9 sites
Sage Investigational Site
Barcelona, 8003
Sage Investigational Site
Barcelona, 8035
Sage Investigational Site
Barcelona, 8041
Sage Investigational Site
Collado Villalba, 28040
Sage Investigational Site
Madrid, 28031
Sage Investigational Site
Oviedo, 33011
Sage Investigational Site
Sabadell, 8208
Sage Investigational Site
Valladolid, 47012
Sage Investigational Site
Vigo, 36213
United Kingdom5 sites
Sage Investigational Site
Headington, Oxford, OX3 7JX
Sage Investigational Site
Maidstone, ME16 9NW
Sage Investigational Site
Morpeth, Northumberland, NE61 2NU
Sage Investigational Site
Preston, Lancashire, PR2 8DW
Sage Investigational Site
Runwell, Essex, SS11 7XX
About this study
Official title: A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
Read the detailed description
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
- Conditions
- Depression, Postpartum
- Being tested
- SAGE-217, Placebo
- Keywords
- SAGE-217, Postpartum depression
- Medical subject headings
- Depression, Postpartum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SAGE-217Drug
SAGE-217 oral capsules.
PlaceboDrug
SAGE-217 matched-placebo oral capsules.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Participants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days. Receives: Drug: Placebo |
| SAGE-217 50 mg | Experimental | Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days. Receives: Drug: SAGE-217 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for the analysis.
Measured: Baseline and Day 15
Secondary outcomes (11)
Change From Baseline in the 17-item HAM-D Total Score
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. MMRM was used for the analysis.
Measured: Baseline, Days 3, 28 and 45
Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score
The CGI-S is a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis. A participant was assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= extremely ill participants. A lower score indicates a better outcome. A negative change from baseline indicates improvement. MMRM was used for the analysis.
Measured: Baseline and Day 15
Percentage of Participants With HAM-D Response
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D response was defined as a ≥50% reduction in HAM-D total score from baseline.
Measured: Days 15 and 45
Percentage of Participants With HAM-D Remission
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D remission was defined as having a HAM-D total score of ≤7.
Measured: Days 15 and 45
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. Response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The CGI-I was only rated at posttreatment assessments. By definition, all CGI-I assessments are evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of "very much improved" or "much improved."
Measured: Day 15
Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
The 14-item HAM-A was used to rate the severity of symptoms of anxiety. Each 14-items were defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A total score was calculated as the sum of the 14 individual item scores. The scoring for HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe), with a total score range of 0 to 56 where <17 indicated mild severity, 18 to 24, mild to moderate severity, and 25 to 30, moderate to severe severity. A negative change from baseline in HAM-A total score indicated improvement.
Measured: Baseline and Day 15
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item is rated on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from baseline in MADRS total score indicated improvement.
Measured: Baseline and Day 15
Change From Baseline in HAM-D Subscale
17-item HAM-D scale is used for severity of depression. HAM-D subscales: Core subscale(depressed mood, feelings of guilt, suicide, work and activities, and retardation/20x100; Anxiety subscale[anxiety(psychic and somatic), somatic symptoms (gastrointestinal and general), hypochondriasis, and insight loss of weight]/18x100; Bech-6 subscale(depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, and somatic symptoms general)/22x100; Maier score(depressed mood, feelings of guilt, work and activities, retardation, agitation, and anxiety psychic)/24x100. Each item was scored in range of 0 to 2 or 0 to 4 (0=none to 2 or 4=severe), higher score=more depression. 4 Subscale scores were calculated as sum of individual rating scores related to each subscale, divided by total possible score within subscale, multiplied by 100. Scores were transformed to scale of 0 to 100, with higher scores=more severe depression. Negative CFB=improvement. MMRM was used for analysis.
Measured: Baseline and Day 15
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score
The EPDS is a self-rated depressive symptom severity scale specific to the perinatal period which consists of 10 individual items. Each item is rated on a 4-point scale ranging from 0 to 3 points. The EPDS total score is calculated as the sum of the 10 individual item scores, ranging from 0 points to 30 points with a higher score indicating more depression. A negative change indicates improvement.
Measured: Baseline, Days 3, 8,15, 21, 28 and 45
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score
The PHQ-9 is a self-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants responses to 9 specific questions as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The score were calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression; and 20 to 27 = severe depression. The PHQ-9 total score ranges from 1 to 27 with a higher score indicating more depression. A negative change from baseline indicates reduced depression. MMRM was used for the analysis.
Measured: Baseline, Days 3, 8,15, 21, 28 and 45
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.
Measured: Up to Day 45
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2020
- Study start8 Jun 2020
- Primary completion15 Mar 2022
- Study completion12 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Depression, PostpartumStudies of the same condition, open and under way.
- More trials run by BiogenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biogen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04442503
- Sponsor's protocol ID
- 217-PPD-301
- Other IDs
- 2020-001424-34
- Status last verified
- Nov 2023
- First submitted
- 18 Jun 2020
- Last updated
- 30 Nov 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Publications
Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J. Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry. 2023 Sep 1;180(9):668-675. doi: 10.1176/appi.ajp.20220785. Epub 2023 Jul 26.
PubMed 37491938
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression
- ClinicalTrials.gov ID
- NCT04442503
- Acronym / sponsor ID
- 217-PPD-301
- Conditions
- Depression, Postpartum
- Keywords
- SAGE-217, Postpartum depression
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- BiogenIndustry (pharma, biotech, devices)
- Study start
- 8 Jun 2020 (actual)
- Primary completion
- 15 Mar 2022 (actual)
- Study completion
- 12 Apr 2022 (actual)
- First posted
- 22 Jun 2020 (actual)
- Results
- Posted 22 Jun 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
Detailed description
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboParticipants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days. |
| SAGE-217 50 mg | Experimental | Drug: SAGE-217Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP.
- Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT).
- Participant is ≤12 months postpartum at screening and Day 1.
Key exclusion criteria (6 listed)
- Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD.
- Participant has active psychosis per investigator assessment.
- Participant has a medical history of nonfebrile seizures.
- Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
- Participant has a history of sleep apnea.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SAGE-217SAGE-217 oral capsules. | Drug | SAGE-217 50 mg |
| PlaceboSAGE-217 matched-placebo oral capsules. | Drug | Placebo |
Primary outcome
Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15
Time frame: Baseline and Day 15
The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for the analysis.
11 secondary outcomes
Change From Baseline in the 17-item HAM-D Total Score
Time frame: Baseline, Days 3, 28 and 45
Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score
Time frame: Baseline and Day 15
Percentage of Participants With HAM-D Response
Time frame: Days 15 and 45
Percentage of Participants With HAM-D Remission
Time frame: Days 15 and 45
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
Time frame: Day 15
Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score
Time frame: Baseline and Day 15
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
Time frame: Baseline and Day 15
Change From Baseline in HAM-D Subscale
Time frame: Baseline and Day 15
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score
Time frame: Baseline, Days 3, 8,15, 21, 28 and 45
Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score
Time frame: Baseline, Days 3, 8,15, 21, 28 and 45
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Time frame: Up to Day 45
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37491938Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J. Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry. 2023 Sep 1;180(9):668-675. doi: 10.1176/appi.ajp.20220785. Epub 2023 Jul 26.
- Individual participant dataSharing planned: Yes. In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Related trials for Depression, Postpartum
RecruitingPhase 1
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
Pain, Postpartum Depression
Recruiting
Restoring Emotional Needs With Exogenous Ketones for Women With Postpartum Depression
Postpartum Depression (PPD)
Recruiting
Treatment With Repetitive Transcranial Magnetic Stimulation in Peripartal Depression
Depression During Pregnancy, Postpartum Depression (PPD)
Enrolling by invitation
Intervention to Reduce HIV Related Stigma Among Pregnant and Postpartum Women
HIV, HIV - Human Immunodeficiency Virus
RecruitingEarly Phase 1
A Web-based Intervention Program for Postpartum Depression
Postpartum Depression (PPD), Web-based Intervention
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
82 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing SAGE-217 in people with Depression, Postpartum, run by Biogen at 82 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 82 sites in United States, Spain, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jun 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 (time frame: Baseline and Day 15). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04442503, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.